DK175505B1 - 1-substituerede 3-(1-[cyan eller carbamoyl]-1,1-diphenylmethyl)piperidin-forbindelser og deres anvendelse til fremstilling af et lægemiddel til behandling af sygdomme forbundet med ændret motilitet og/eller tonus af glatmuskel....... - Google Patents

1-substituerede 3-(1-[cyan eller carbamoyl]-1,1-diphenylmethyl)piperidin-forbindelser og deres anvendelse til fremstilling af et lægemiddel til behandling af sygdomme forbundet med ændret motilitet og/eller tonus af glatmuskel....... Download PDF

Info

Publication number: DK175505B1
Authority: DK; Denmark
Prior art keywords: dichloromethane; diphenylmethyl; give; mixture; concentrated
Prior art date: 1988-11-01

Application number

DK199100799A

Other languages

Danish (da)

English (en)

Other versions

DK79991D0 (da

DK79991A (da

Inventor

Peter Edward Cross

Alexander Roderick Mackenzie

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-01

Filing date

1991-04-30

Publication date

2004-11-15

1991-04-30 Application filed by Pfizer filed Critical Pfizer

1991-04-30 Publication of DK79991D0 publication Critical patent/DK79991D0/da

1991-06-28 Publication of DK79991A publication Critical patent/DK79991A/da

2004-11-15 Application granted granted Critical

2004-11-15 Publication of DK175505B1 publication Critical patent/DK175505B1/da

Links

210000002460 smooth muscle Anatomy 0.000 title claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 7
230000004899 motility Effects 0.000 title claims abstract description 7
238000011282 treatment Methods 0.000 title claims abstract description 6
150000003053 piperidines Chemical class 0.000 title claims description 8
239000003814 drug Substances 0.000 title claims description 6
238000004519 manufacturing process Methods 0.000 title claims description 4
125000004093 cyano group Chemical group *C#N 0.000 title abstract description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 title description 5
208000035475 disorder Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 66
-1 -(CH2)nOH Chemical group 0.000 claims abstract description 15
150000003839 salts Chemical class 0.000 claims abstract description 15
201000010099 disease Diseases 0.000 claims abstract description 6
208000002551 irritable bowel syndrome Diseases 0.000 claims abstract 2
SYRONFKSCBDOAQ-MHZLTWQESA-N 2-[(3r)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]piperidin-3-yl]-2,2-diphenylacetonitrile Chemical compound C=1C=CC=CC=1C([C@@H]1CN(CCC=2C=C3CCOC3=CC=2)CCC1)(C#N)C1=CC=CC=C1 SYRONFKSCBDOAQ-MHZLTWQESA-N 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 8
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract description 3
229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract description 3
229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000003373 pyrazinyl group Chemical group 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 225
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 96
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 66
239000000203 mixture Substances 0.000 description 63
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
239000010410 layer Substances 0.000 description 52
238000002360 preparation method Methods 0.000 description 52
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
229910000027 potassium carbonate Inorganic materials 0.000 description 35
239000000243 solution Substances 0.000 description 35
238000010992 reflux Methods 0.000 description 29
239000003921 oil Substances 0.000 description 25
235000011181 potassium carbonates Nutrition 0.000 description 25
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
239000002027 dichloromethane extract Substances 0.000 description 24
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000007795 chemical reaction product Substances 0.000 description 21
238000005481 NMR spectroscopy Methods 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
238000004440 column chromatography Methods 0.000 description 18
239000000377 silicon dioxide Substances 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 17
238000005160 1H NMR spectroscopy Methods 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
238000000921 elemental analysis Methods 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
229910000029 sodium carbonate Inorganic materials 0.000 description 12
239000007787 solid Substances 0.000 description 12
MUJCSMYPEMHLLQ-UHFFFAOYSA-N 2,2-diphenyl-2-piperidin-3-ylacetamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N)C1CCCNC1 MUJCSMYPEMHLLQ-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
238000000034 method Methods 0.000 description 8
235000015320 potassium carbonate Nutrition 0.000 description 8
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 8
239000007858 starting material Substances 0.000 description 7
FBVXCPVQUYFTRV-SFHVURJKSA-N 2,2-diphenyl-2-[(3r)-piperidin-3-yl]acetonitrile Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C#N)[C@H]1CCCNC1 FBVXCPVQUYFTRV-SFHVURJKSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
229910052740 iodine Inorganic materials 0.000 description 6
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
FBVXCPVQUYFTRV-UHFFFAOYSA-N 2,2-diphenyl-2-piperidin-3-ylacetonitrile Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C#N)C1CCCNC1 FBVXCPVQUYFTRV-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
239000000556 agonist Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
239000000725 suspension Substances 0.000 description 5
210000003437 trachea Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000003405 ileum Anatomy 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000001387 anti-histamine Effects 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
230000008602 contraction Effects 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
150000002825 nitriles Chemical class 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
210000005245 right atrium Anatomy 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
210000003932 urinary bladder Anatomy 0.000 description 3
OXHPTABOQVHKLN-UHFFFAOYSA-N 1-(2-bromoethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCBr)C=C1 OXHPTABOQVHKLN-UHFFFAOYSA-N 0.000 description 2
IAZCKSJRRRXZEY-UHFFFAOYSA-N 1-(2-bromoethyl)-4-methylbenzene Chemical compound CC1=CC=C(CCBr)C=C1 IAZCKSJRRRXZEY-UHFFFAOYSA-N 0.000 description 2
HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000000739 antihistaminic agent Substances 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
208000007784 diverticulitis Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
125000005948 methanesulfonyloxy group Chemical group 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000003387 muscular Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
210000001747 pupil Anatomy 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
ZPHLFTYEXGBTQT-UHFFFAOYSA-N (2-bromo-1,1-dichloroethyl)benzene Chemical compound ClC(Cl)(CBr)C1=CC=CC=C1 ZPHLFTYEXGBTQT-UHFFFAOYSA-N 0.000 description 1
UVZVRUOXFQXFTC-UHFFFAOYSA-N (2-bromo-1-chloroethyl)benzene Chemical compound BrCC(Cl)C1=CC=CC=C1 UVZVRUOXFQXFTC-UHFFFAOYSA-N 0.000 description 1
FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
YAFMYKFAUNCQPU-UHFFFAOYSA-N 1-(2-bromoethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CCBr)C=C1 YAFMYKFAUNCQPU-UHFFFAOYSA-N 0.000 description 1
YGYPCEPMUOKONV-UHFFFAOYSA-N 1-(2-chloroethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CCCl)=C1 YGYPCEPMUOKONV-UHFFFAOYSA-N 0.000 description 1
DBDVAKGHPZJLTH-UHFFFAOYSA-N 1-(2-phenylethyl)piperidine Chemical compound C1CCCCN1CCC1=CC=CC=C1 DBDVAKGHPZJLTH-UHFFFAOYSA-N 0.000 description 1
CPHLODVMQBMDNC-UHFFFAOYSA-N 1-(3-bromopropyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCCBr)C=C1 CPHLODVMQBMDNC-UHFFFAOYSA-N 0.000 description 1
JGOMHEJZAZWLBC-UHFFFAOYSA-N 1-[2-(3-methylphenyl)ethyl]piperidine Chemical compound CC1=CC=CC(CCN2CCCCC2)=C1 JGOMHEJZAZWLBC-UHFFFAOYSA-N 0.000 description 1
LOQOVOPGCUKSNT-UHFFFAOYSA-N 1-[2-(4-methylphenyl)ethyl]piperidine Chemical compound C1=CC(C)=CC=C1CCN1CCCCC1 LOQOVOPGCUKSNT-UHFFFAOYSA-N 0.000 description 1
XJWVCWQKZQENDS-UHFFFAOYSA-N 1-bromopropan-2-ylbenzene Chemical compound BrCC(C)C1=CC=CC=C1 XJWVCWQKZQENDS-UHFFFAOYSA-N 0.000 description 1
ADGDHLKQWFIASU-UHFFFAOYSA-N 2,2-diphenyl-2-piperidin-1-ylacetonitrile Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C#N)N1CCCCC1 ADGDHLKQWFIASU-UHFFFAOYSA-N 0.000 description 1
NEBPTMCRLHKPOB-UHFFFAOYSA-N 2,2-diphenylacetonitrile Chemical compound C=1C=CC=CC=1C(C#N)C1=CC=CC=C1 NEBPTMCRLHKPOB-UHFFFAOYSA-N 0.000 description 1
LALSYIKKTXUSLG-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCCC2=C1 LALSYIKKTXUSLG-UHFFFAOYSA-N 0.000 description 1
IPSIYKHOHYJGMO-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-yl)ethanol Chemical compound OCCC1=CC=C2OCCC2=C1 IPSIYKHOHYJGMO-UHFFFAOYSA-N 0.000 description 1
LKFBPUOGEAPFGQ-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-5-yl)ethanol Chemical compound OCCC1=CC=C2CCCC2=C1 LKFBPUOGEAPFGQ-UHFFFAOYSA-N 0.000 description 1
PCPSVKFJTUWOMC-DEOSSOPVSA-N 2-[(3r)-1-(4-methylphenyl)sulfonylpiperidin-3-yl]-2,2-diphenylacetonitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C[C@@H](C(C#N)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCC1 PCPSVKFJTUWOMC-DEOSSOPVSA-N 0.000 description 1
DAHHEUQBMDBSLO-UHFFFAOYSA-N 2-bromo-1-phenylethanol Chemical compound BrCC(O)C1=CC=CC=C1 DAHHEUQBMDBSLO-UHFFFAOYSA-N 0.000 description 1
JJFOBACUIRKUPN-UHFFFAOYSA-N 2-bromoethoxybenzene Chemical compound BrCCOC1=CC=CC=C1 JJFOBACUIRKUPN-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
CWLOASLNWGIODY-UHFFFAOYSA-N 3-bromo-2-phenylpropanamide Chemical compound C(N)(=O)C(CBr)C1=CC=CC=C1 CWLOASLNWGIODY-UHFFFAOYSA-N 0.000 description 1
XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
GGEGIBVNJACVCA-UHFFFAOYSA-N 4-(2-bromoethyl)benzamide Chemical compound NC(=O)C1=CC=C(CCBr)C=C1 GGEGIBVNJACVCA-UHFFFAOYSA-N 0.000 description 1
NNNRGWOWXNCGCV-UHFFFAOYSA-N 4-(2-bromoethyl)benzonitrile Chemical compound BrCCC1=CC=C(C#N)C=C1 NNNRGWOWXNCGCV-UHFFFAOYSA-N 0.000 description 1
DYYVTFCYVZEQDG-UHFFFAOYSA-N 4-(2-bromoethyl)phenol Chemical compound OC1=CC=C(CCBr)C=C1 DYYVTFCYVZEQDG-UHFFFAOYSA-N 0.000 description 1
NNLAGIHHJWDWIQ-UHFFFAOYSA-N 4-(2-chloroethyl)-2-methoxyphenol Chemical compound COC1=CC(CCCl)=CC=C1O NNLAGIHHJWDWIQ-UHFFFAOYSA-N 0.000 description 1
QQZXJFCQSWJIGL-UHFFFAOYSA-N 4-chloro-4h-1,3-benzodioxine Chemical compound C1=CC=C2C(Cl)OCOC2=C1 QQZXJFCQSWJIGL-UHFFFAOYSA-N 0.000 description 1
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
JRKZQRRYNCMSCB-UHFFFAOYSA-N 5-(2-bromoethyl)-2,3-dihydro-1-benzofuran Chemical compound BrCCC1=CC=C2OCCC2=C1 JRKZQRRYNCMSCB-UHFFFAOYSA-N 0.000 description 1
DWSUJONSJJTODA-UHFFFAOYSA-N 5-(chloromethyl)-1,3-benzodioxole Chemical compound ClCC1=CC=C2OCOC2=C1 DWSUJONSJJTODA-UHFFFAOYSA-N 0.000 description 1
FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
BIGVVTGYXZQHKR-UHFFFAOYSA-N BrCCC1OC2=C(C1)C=CC=C2 Chemical compound BrCCC1OC2=C(C1)C=CC=C2 BIGVVTGYXZQHKR-UHFFFAOYSA-N 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000018569 Respiratory Tract disease Diseases 0.000 description 1
241000269400 Sirenidae Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
241000009298 Trigla lyra Species 0.000 description 1
GZDAOODJXSZNFQ-QGZVFWFLSA-N [(3r)-1-(4-methylphenyl)sulfonylpiperidin-3-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1CN(S(=O)(=O)C=2C=CC(C)=CC=2)CCC1 GZDAOODJXSZNFQ-QGZVFWFLSA-N 0.000 description 1
ZAFQKZUIAXOIGH-FKKOFPAZSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid;(3r)-piperidin-3-ol Chemical compound O[C@@H]1CCCNC1.C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C ZAFQKZUIAXOIGH-FKKOFPAZSA-N 0.000 description 1
DCDOYTYLMUZKIG-DLGLCQKISA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid;1-hydroxypiperidine Chemical compound ON1CCCCC1.C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C DCDOYTYLMUZKIG-DLGLCQKISA-N 0.000 description 1
JNDZKPICJFWIGC-UHFFFAOYSA-N [4-(2-bromoethyl)phenyl]methanol Chemical compound OCC1=CC=C(CCBr)C=C1 JNDZKPICJFWIGC-UHFFFAOYSA-N 0.000 description 1
MHOJNMBUNDNWIM-UHFFFAOYSA-N acetamide azepane Chemical class C(C)(=O)N.N1CCCCCC1 MHOJNMBUNDNWIM-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003710 aryl alkyl group Chemical class 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical class C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000004927 clay Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000028299 esophageal disease Diseases 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
238000009428 plumbing Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical group [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Filters That Use Time-Delay Elements (AREA)
Bending Of Plates, Rods, And Pipes (AREA)
Position Fixing By Use Of Radio Waves (AREA)
Steroid Compounds (AREA)

DK199100799A 1988-11-01 1991-04-30 1-substituerede 3-(1-[cyan eller carbamoyl]-1,1-diphenylmethyl)piperidin-forbindelser og deres anvendelse til fremstilling af et lægemiddel til behandling af sygdomme forbundet med ændret motilitet og/eller tonus af glatmuskel....... DK175505B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8825505		1988-11-01
GB888825505A GB8825505D0 (en)	1988-11-01	1988-11-01	Therapeutic agents
PCT/EP1989/001300 WO1990005133A1 (fr)	1988-11-01	1989-10-26	Antagonistes recepteurs muscariniques
EP8901300		1989-10-26

Publications (3)

Publication Number	Publication Date
DK79991D0 DK79991D0 (da)	1991-04-30
DK79991A DK79991A (da)	1991-06-28
DK175505B1 true DK175505B1 (da)	2004-11-15

Family

ID=10646093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK199100799A DK175505B1 (da)	1988-11-01	1991-04-30	1-substituerede 3-(1-[cyan eller carbamoyl]-1,1-diphenylmethyl)piperidin-forbindelser og deres anvendelse til fremstilling af et lægemiddel til behandling af sygdomme forbundet med ændret motilitet og/eller tonus af glatmuskel.......

Country Status (13)

Country	Link
US (1)	US5422358A (fr)
EP (2)	EP0376358A1 (fr)
JP (1)	JPH0791268B2 (fr)
AT (1)	ATE153019T1 (fr)
CA (1)	CA1328454C (fr)
DE (1)	DE68928045T2 (fr)
DK (1)	DK175505B1 (fr)
ES (1)	ES2102353T3 (fr)
FI (1)	FI97468C (fr)
GB (1)	GB8825505D0 (fr)
GR (1)	GR3023974T3 (fr)
PT (1)	PT92158B (fr)
WO (1)	WO1990005133A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6017931A (en) *	1994-03-01	2000-01-25	Fmc Corporation	Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US5569664A (en) *	1995-02-16	1996-10-29	Fmc Corporation	Insecticidal n-(substituted arylmethyl)-4-[bis(substituted phenyl) methyl]pi
US5639763A (en) *	1994-03-01	1997-06-17	Fmc Corporation	Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
DE69615214T2 (de) *	1995-10-13	2002-06-27	Banyu Pharmaceutical Co., Ltd.	Substituierte heteroaromatische derivate
PE92198A1 (es) *	1996-08-01	1999-01-09	Banyu Pharma Co Ltd	Derivados de 1,4-piperidina disustituida que contienen fluor
ES2203327B1 (es) *	2002-06-21	2005-06-16	Almirall Prodesfarma, S.A.	Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) *	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
JP2007524641A (ja) *	2003-07-11	2007-08-30	セラヴァンス，インコーポレーテッド	置換４−アミノ−１−ベンジルピペリジン化合物
WO2006097848A1 (fr) *	2005-03-17	2006-09-21	Pfizer Inc.	Inhibiteurs de maturation du virion du vih-1, compositions et traitements les utilisant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2139628A1 (en)	1971-05-28	1973-01-12	Lipha	5-(4-aryl piperazino-alkyl and alkylene) indans - with tranquillizing activity
US4032642A (en) *	1974-12-11	1977-06-28	A. H. Robins Company, Incorporated	1-Substituted-4-benzylpiperidines
US4002766A (en) *	1974-12-26	1977-01-11	A. H. Robins Company, Incorporated	Antiarrhythmia methods
US4242261A (en) *	1979-07-19	1980-12-30	A. H. Robins Company, Inc.	Production of methylene-cycloamines
FR2531702A1 (fr) *	1982-08-16	1984-02-17	Synthelabo	Derives de phenethyl-1a-phenylperidine-3-propanenitrile, leur preparation et leur application en therapeutique
FI842738A7 (fi)	1983-07-14	1985-01-15	Syntex Inc	Aroyylibentsofuraani- ja bentsotiofeenietikka- ja propionihapot.
US4594343A (en) *	1984-10-19	1986-06-10	Shanklin Jr James R	1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
IL76583A (en)	1984-10-19	1988-08-31	Robins Co Inc A H	1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
EP0235463A3 (fr) *	1985-12-20	1990-01-17	A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation)	Arylalkyl et arylalkylène piperidines substitués sur l'azote utilisés comme agents antihistaminiques cardiovasculaires et antisécrétion
US4810713A (en) *	1985-12-20	1989-03-07	A. H. Robins Company, Incorporated	Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
IN163948B (fr) *	1986-01-17	1988-12-10	Robins Co Inc A H
GB8824262D0 (en) *	1988-10-17	1988-11-23	Pfizer Ltd	Therapeutic agents
GB8906166D0 (en) *	1989-03-17	1989-05-04	Pfizer Ltd	Therapeutic agents
US7078474B2 (en)	2004-07-07	2006-07-18	E. I. Dupont De Nemours And Company	Thermally curable coating compositions

1988
- 1988-11-01 GB GB888825505A patent/GB8825505D0/en active Pending
1989
- 1989-09-29 CA CA000615036A patent/CA1328454C/fr not_active Expired - Fee Related
- 1989-10-26 EP EP89202720A patent/EP0376358A1/fr active Pending
- 1989-10-26 ES ES89912443T patent/ES2102353T3/es not_active Expired - Lifetime
- 1989-10-26 AT AT89912443T patent/ATE153019T1/de not_active IP Right Cessation
- 1989-10-26 DE DE68928045T patent/DE68928045T2/de not_active Expired - Fee Related
- 1989-10-26 WO PCT/EP1989/001300 patent/WO1990005133A1/fr not_active Ceased
- 1989-10-26 EP EP89912443A patent/EP0441852B1/fr not_active Expired - Lifetime
- 1989-10-26 JP JP1511557A patent/JPH0791268B2/ja not_active Expired - Fee Related
- 1989-10-26 US US07/678,941 patent/US5422358A/en not_active Expired - Lifetime
- 1989-10-30 PT PT92158A patent/PT92158B/pt not_active IP Right Cessation
1991
- 1991-04-30 DK DK199100799A patent/DK175505B1/da not_active IP Right Cessation
- 1991-04-30 FI FI912085A patent/FI97468C/fi active
1997
- 1997-07-02 GR GR970401625T patent/GR3023974T3/el unknown

Also Published As

Publication number	Publication date
EP0441852A1 (fr)	1991-08-21
PT92158B (pt)	1995-07-18
PT92158A (pt)	1990-05-31
EP0376358A1 (fr)	1990-07-04
DE68928045T2 (de)	1997-08-28
US5422358A (en)	1995-06-06
FI912085A0 (fi)	1991-04-30
EP0441852B1 (fr)	1997-05-14
FI97468B (fi)	1996-09-13
CA1328454C (fr)	1994-04-12
FI97468C (fi)	1996-12-27
DK79991D0 (da)	1991-04-30
ATE153019T1 (de)	1997-05-15
GB8825505D0 (en)	1988-12-07
JPH0791268B2 (ja)	1995-10-04
DK79991A (da)	1991-06-28
DE68928045D1 (de)	1997-06-19
GR3023974T3 (en)	1997-10-31
ES2102353T3 (es)	1997-08-01
JPH04500521A (ja)	1992-01-30
WO1990005133A1 (fr)	1990-05-17

Legal Events

Date	Code	Title	Description
2009-06-08	PBP	Patent lapsed	Country of ref document: DK

Publication	Publication Date	Title
US5096890A (en)	1992-03-17	Pyrrolidine derivatives
US5534525A (en)	1996-07-09	Lactam derivatives
DK158348B (da)	1990-05-07	Terapeutisk virksomme n-substituerede 4-oxypiperidinderivater samt farmaceutisk praeparat med indhold heraf
EP0505377B1 (fr)	1996-01-03	Antagonistes de recepteurs muscariniques
CZ283619B6 (cs)	1998-05-13	Použití derivátů kyseliny benzoové pro výrobu farmaceutických prostředků, deriváty kyseliny benzoo vé, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
JP3590589B2 (ja)	2004-11-17	Ｃｎｓ障害の処置のための１−アレーンスルホニル−２−アリール−ピロリジン及びピペリジン誘導体
HUT75878A (en)	1997-05-28	N-substituted azaheterocyclic carboxylic acids and esters thereof, pharmaceutical compositions containing them, process for their preparation and their use for treatment of neurogenic inflammations
HUT55387A (en)	1991-05-28	Process for producing piperidine derivatives
EP0350309B1 (fr)	1992-11-11	Dérivés de pipéridine
US5418229A (en)	1995-05-23	Muscarinic receptor antagonists
EP0508988B1 (fr)	1994-03-02	Antagonistes de recepteurs muscariniques
EP0441852B1 (fr)	1997-05-14	Antagonistes recepteurs muscariniques
US5486527A (en)	1996-01-23	Anticholinergic agents
JP2002532480A (ja)	2002-10-02	モルホリノン及びモルホリン誘導体、ならびにその使用
CA2072575C (fr)	2000-08-08	Agents anticholinergiques
US5607950A (en)	1997-03-04	Muscarinic receptor antagonists
US5932594A (en)	1999-08-03	Muscarinic receptor antagonists
JPH1171350A (ja)	1999-03-16	ヒドロキシピペリジン化合物およびその剤
FI96024B (fi)	1996-01-15	Menetelmä terapeuttisesti käyttökelpoisten 3-fenyyliglutarimidijohdannaisten valmistamiseksi
EP0502031B1 (fr)	1997-08-20	Acides carboxyliques azaheterocycliques a substitution n et preparation pharmaceutique
US6008223A (en)	1999-12-28	Therapeutic compounds
WO2001025202A1 (fr)	2001-04-12	Procede de preparation d'intermediaire de la paroxetine